More than three years after Deciphera Pharmaceuticals’ first approval, the company appears to be on the precipice of achieving a second commercial product. Oral tumor treatment vimseltinib passed the ...
Free patient disease education videos from the End Brain Cancer Initiative's “New Developments in PCNSL Treatment” ...
Add Yahoo as a preferred source to see more of our stories on Google. (Reuters) -Deciphera Pharmaceuticals said on Monday Japan's Ono Pharmaceutical Co will acquire the cancer drugmaker for $2.4 ...
Japanese biotech Ono Pharmaceutical is acquiring Deciphera Pharmaceuticals for $2.4 billion, the companies announced Monday. The move serves to bolster Ono’s cancer pipeline, with oncology pinpointed ...
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve ...
Ono Pharmaceutical of Japan said Monday it will acquire Deciphera Pharmaceuticals, a Boston-based maker of cancer drugs, for $2.4 billion. The all-cash deal values Diciphera at $25.60 per share, or a ...
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve ...
Our estimates show that Qinlock 2L KIT exon 11+17/18 mutation indication sales guidance is unlikely to be achieved due to fractional incidence. Deciphera Pharmaceuticals is expecting a Phase III ...
Deciphera Pharmaceuticals Inc. said Monday it has agreed to be acquired by Japan’s Ono Pharmaceutical Co. Ltd in an all-cash deal valued at $2.4 billion. Under the terms of the deal, Ono JP:4528 will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results